Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer.
OBJECTIVE
To evaluate the impact of highly active antiretroviral therapy (HAART) on survival in HIV infected patients with non-small-cell lung cancer (NSCLC).


METHODS
All consecutive HIV infected patients with NSCLC diagnosed between 06/1996 and 03/2007 at two University hospitals in Paris (France) were prospectively followed until death. The association between survival and clinical and biological factors was analyzed by univariate and multivariate models. Survival analysis was performed by Kaplan-Meier estimates and the Cox proportional hazards regression model.


RESULTS
During the study period, NSCLC was diagnosed in 49 consecutive HIV infected patients (median age 46 years); 84% had advanced disease. Median survival was 8.1 months (range 5-10 months). In multivariate analysis, baseline parameters with significant positive impact on survival included performance status (PS) < or =1 (HR=0.2, 95%CI [0.09, 0.46], p=0.0001), stage I-II disease (HR=0.15, 95%CI [0.04, 0.53], p=0.003), and use of HAART (HR=0.4, 95%CI [0.2, 0.9], p=0.027).


CONCLUSIONS
HAART is a good prognostic factor for survival in HIV infected patients with NSCLC. Stage of disease and PS are two other valid survival prognostic factors.
Lavolé
Armelle
A
Service de Pneumologie et Réanimation, Hôpital Tenon, APHP and Faculté de Médecine Pierre et Marie Curie, Université Paris VI, Paris, France. armelle.lavole@tnn.aphp.fr
Chouaïd
Christos
C
Baudrin
Laurence
L
Wislez
Marie
M
Raguin
Gilles
G
Pialoux
Gilles
G
Girard
Pierre-Marie
PM
Milleron
Bernard
B
Cadranel
Jacques
J
D023241:Antiretroviral Therapy, Highly Active; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018450:Disease Progression; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D016019:Survival Analysis; D014779:Virus Replication / Q000187:drug effects